Request for Review: Standardized template with key considerations for a benefit/risk assessment for the Comirnaty COVID-19 mRNA vaccine

The proposed mRNA BioNTech/Comirnaty manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Working Group encourages the Brighton Collaboration community to peer review this template by the end of the day Tuesday, February 20th, 2024.

• View the manuscript: A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Comirnaty COVID-19 mRNA vaccine to prevent disease caused by SARS-CoV-2 viruses

• Click here to complete the peer review form >